Saturday, November 12, 2011

The GLP-1 Agonists: Which Is the Winner?

With the FDA approval of Bydureon in January 2012, there will be three injectable GLP-1 agonists available for the treatment of Type 2 Diabetes.

The battle of the GLP-1's will shortly be in full swing.

Each of the injectable GLP-1 agonists (Byetta, Victoza and Bydureon) are incretin-based therapies.

Incretins are hormones that are released by the gut in response to a sugar load from a meal.

Once released, the incretins stimulate insulin secretion, reduce glucagon secretion, and slow the transit of food in your gut.